



233553

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID: Patient Group No: Physician Office Address: Drug Name (specify drug)			Date: Patient Date Of Birth: Patient Phone:	Phy Spe Phy		Office	Telephone:
Rou	antity: ute of Administration: gnosis:		Expected Length of Therap				
Cor							
Ple :	ase check the appropriat What is the patient's dia Breast cancer (If chec		able question.				
	Other, please specify.	stions)					
2.	Is the patient currently re	eceiving treatment with the	requested drug?	Y		N	
3.	Is there evidence of una	cceptable toxicity on the cu	rrent regimen?	Y		N	
4.	Is there evidence of dise	ease progression while on the	ne current regimen?	Y		N	
5.	What is the clinical setting Recurrent disease (If	ng in which the requested d checked, go to 6)	rug will be used?				
	Advanced disease (If						
	Metastatic disease (If						
	Other, please specify	. (If checked, no further que	stions)				
6.	What is the patient's hor documentation of hormo	one receptor (HR) status.	? ACTION REQUIRED: Please at	tach			
	Negative (If checked,						
	Unknown (If checked, ACTION REQUIRED:	ntation		Ш			
7.	What is the patient's hur	man epidermal growth facto	r receptor 2 (HER2) status? ACTI n epidermal growth factor recepto	ON or 2			
	Positive (If checked, r	no further questions)					
	Negative (If checked.	ao to 8)					

ı							
	Unknown (If checked, no further questions)						
	ACTION REQUIRED: Submit supporting documentation						
8.	Does the patient have a documented PIK3CA mutation? ACTION REQUIRED: If Yes, please attach laboratory test results.						
	Yes (If checked, go to 9)						
	No (If checked, no further questions)						
	Unknown (If checked, no further questions)						
	ACTION REQUIRED: Submit supporting documentation						
9.	Will the requested drug be used in combination with fulvestrant?	Y		N			
10.	Has the disease progressed during or following treatment with an endocrine-based regimen?	Y		N			
I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.							

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.